US panel narrowly backs Schering-Plough's PegIntron for melanoma
This article was originally published in Scrip
Executive Summary
The US FDA's outside oncologic advisors narrowly recommended approval of Schering-Plough's PegIntron (pegylated interferon alfa-2b) for adjuvant treatment of melanoma, finding it to be a more convenient and potentially less toxic alternative to the current standard of care, high-dose interferon.